1. Background {#sec0001}
=============

Miliary tuberculosis is a fatal disease caused by hematogenous dissemination of *Mycobacterium tuberculosis* infection. It is also a rare cause of acute respiratory distress syndrome (ARDS). In many cases, the prognosis of miliary tuberculosis can be improved by introducing effective anti-tuberculosis agents; however, elderly patients and patients with ARDS are likely to suffer a poor prognosis. Only a few reports have described ARDS associated with miliary tuberculosis, with mortality reported to be 33--100% [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009]. Moreover, due to poor prognoses, few cases have been reported in which treatment was found to be effective in improving serious conditions [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0010], [@bib0011]. Furthermore, in elderly patients with tuberculosis, older age is considered a risk of mortality, as it relates to decreased function of pulmonary epithelial cells, increased comorbidities, delay in diagnosis due to decreased cognitive ability of patients themselves as well as increased atypical symptoms, and progression of disease state [@bib0012]. Many reported studies to date are from high-prevalence countries, targeting relatively young subjects, and few studies have been conducted in elderly patients with tuberculosis. In recent years, a considerably high proportion of patients with tuberculosis in Japan have characteristically been older patients. In this study, we examined prognostic factors in a population of miliary tuberculosis patients including those with ARDS, which predominantly comprised elderly patients.

2. Methods {#sec0002}
==========

2.1. Patients {#sec0003}
-------------

Over a period of 22 years (January 1, 1994--October 1, 2016), 2293 patients were hospitalized at the National Hospital Organization Omuta Hospital with the diagnosis of tuberculosis. Of these, 70 patients were diagnosed with miliary tuberculosis. Two patients who did not undergo chest CT were excluded from analysis. All patients who died due to tuberculosis did not survive beyond three months. Therefore, the remaining 68 patients were divided into those who survived longer than three months (survivor group: *n *= 53) and those who died within three months of diagnosis (non-survivor group: *n *= 15).

The following clinical information at hospitalization was collected from medical charts: age, sex, history of smoking, alcohol intake, underlying diseases, symptoms, performance status (PS), microbiological data (including the drug sensitivity pattern of *M. tuberculosis* isolates), PaO2/FiO2 ratio, laboratory findings, time from onset to admission, time from admission to anti-tuberculosis therapy, time from onset to anti-tuberculosis therapy, length of hospital stay, presence or absence of ARDS, and mechanical ventilation. Consciousness disturbance was defined as that with the Glasgow Coma Scale (GCS) of 12 or less.

2.2. Diagnosis of miliary tuberculosis {#sec0004}
--------------------------------------

Miliary tuberculosis was diagnosed by one radiologist and two respiratory physicians, based on the observation of randomly distributed, uniformly sized diffuse bilateral nodules on chest CT. A definitive diagnosis of tuberculosis was made when at least one of the following three criteria was met: (1) positive acid-fast bacilli (AFB) smear and/or culture for *M. tuberculosis* from clinical specimens such as sputum, bronchial lavage fluid, pleural fluid, urine, and bone marrow aspirate; (2) histopathological identification of a tuberculosis granuloma in biopsied tissues of lung, pleura and/or bone marrow; or (3) clinical and radiological improvement after anti-tuberculosis treatment.

2.3. Diagnosis of ARDS {#sec0005}
----------------------

ARDS was diagnosed according to the Berlin definition of ARDS, based on chest x-ray and chest CT findings and the PaO2/FiO2 ratio after having excluded all differential diagnoses, such as heart failure, pneumonia, pulmonary haemorrhage, acute interstitial lung disease, and drug reactions [@bib0013].

2.4. Statistical analysis {#sec0006}
-------------------------

Age, PS, platelets, CRP, ALP, total bilirubin, and number of days from hospitalization to the initiation of anti-tuberculosis treatment were comparatively examined between the case group (i.e., patients who died within three months of diagnosis) and the control group (i.e., survivors). Statistical tests were performed using the Wilcoxon rank sum (Mann--Whitney) test. With respect to white blood cell count, neutrophils, AST, ALT, LDH, BUN, creatinine, number of days from onset to hospitalization, and number of days from onset to the initiation of anti-tuberculosis treatment, geometric mean values were comparatively examined between the two groups. In the case of 0 days, logarithmic conversion was performed as 0.1 days.

Next, using the case-control study method, risk factors for death within three months of diagnosis were examined. Based on results from previous studies, old age and ARDS onset were suspected to be strongly associated with the risk of death within three months. Since the present study also yielded similar results (described in the following section), analyses of other associated factors were constantly adjusted for age and presence/absence of ARDS, and odds ratios for each factor were obtained using logistic regression analysis.

Furthermore, in order to assess which of the examined factors were strongly associated, clinically relevant factors with a *p* value \< 0.1 in the analysis adjusted for presence/absence of ARDS were incorporated as the first explanatory variables, and thereafter, variables were selected using the stepwise method.

3. Results {#sec0007}
==========

3.1. Demographic data and clinical characteristics ([Table 1](#tbl0001){ref-type="table"}) {#sec0008}
------------------------------------------------------------------------------------------

The median age of the 68 patients with miliary tuberculosis (18 men and 50 women) was 83.0 years (range, 27--93 years). Most patients were aged 60 years or older (63/68; 91.2%), with a peak in the 80 s (32/68; 47.1%). Ten patients (15%) had a history of smoking, and 8 patients (12%) consumed alcohol. There were 102 underlying diseases in 57 patients: dementia (16), liver disease (8), diabetes (18), connective tissue disease with steroid treatment (9), renal disease (7), heart disease (15), cerebrovascular disease (12), aortic aneurysm (3), neuromuscular disease (3), and malignancy (11). Eight patients (11.8%) had a history of tuberculosis. Symptoms were fever (51/68, 75%), dyspnea (20/68, 29%), cough (19/68, 28%), sputum (14/68, 21%), loss of appetite (44/68, 65%), general malaise (45/68, 66%), consciousness disturbance (8/68, 12%) and lumbar pain (7/68, 10%). The median (range) PS was 3 (1--4). Of the 68 patients with miliary tuberculosis, 13 patients (19%) had ARDS; 11 patients had already developed ARDS at the time of first visit, and the other two developed ARDS during hospitalization.

3.2. Diagnostic findings {#sec0009}
------------------------

Among 26 patients showing only bilateral diffuse nodules on chest CT, 8 had pleural effusion ([Fig. 1](#fig0001){ref-type="fig"}A). Among 29 patients showing partially fused nodules as well as infiltrations, in addition to bilateral diffuse nodules, 11 had pleural effusion ([Fig. 1](#fig0001){ref-type="fig"}B). Among 13 patients who fell under the criteria for ARDS imaging diagnosis and showed ground-glass opacities / infiltrations in the entire lungs in addition to bilateral diffuse nodules, 3 had pleural effusion ([Fig. 1](#fig0001){ref-type="fig"}C).Fig. 1Chest computed tomographic scans showed three patterns: only diffuse nodules exhibiting a random distribution (A); diffuse nodules exhibiting a random distribution with infiltrations (B); and diffuse nodules exhibiting a random distribution with ground glass opacities (C).Fig 1

A definitive diagnosis of tuberculosis was made according to the above-mentioned criteria; 63 patients (93%) were ultimately verified to have *M. tuberculosis*. Of these, 49 had AFB smear-positive clinical specimens during hospitalization, 2 had positive sputum samples by PCR only, and 1 had PCR-positive sputum and bone marrow biopsy tissue showing epithelioid granulomas. Of the AFB smear positive patients, 42 had a positive--PCR for *M. tuberculosis* (MTb) initially. Another 7 patients had a negative--PCR for MTb in the initial investigation, but culture was subsequently positive. The remaining 11 patients had positive cultures during follow-up. In all cases, the presence of *M. tuberculosis* was verified using specimens form the respiratory system or respiratory samples (sputum, fluid from endotracheal tube suction, and bronchial lavage fluid). Moreover, 24 patients also had *M. tuberculosis* culture-positive extrapulmonary specimens (urine, 8; pleural effusion, 6; gastric effusion, 5; blood, 2; and scrotal pus, 12). Subsequently, three patients were confirmed to have tuberculosis by histopathological examination of biopsy tissue (transbronchial biopsy, 1; bone marrow biopsy, 2). As for the remaining two patients, clinical diagnosis was ultimately obtained; these patients had a fever of ≥ 38 °C, and as antibiotics administered for ≥1 week were ineffective, they were referred to our hospital. At the initial visit, one showed only nodules on chest CT, and another showed infiltrations in addition to nodules. Both patients showed improvements in clinical course and imaging findings after treatment with anti-tuberculosis agents was initiated. Based on these courses, the two patients were diagnosed with miliary tuberculosis.

The drug susceptibility test was performed with 57 isolates of *M. tuberculosis*. Of these, 49 isolates (86%) were found to be susceptible to all anti-tuberculosis agents (isoniazid \[H\], rifampicin \[R\], ethambutol \[E\], pyrazinamide \[Z\], cycloserine, para-aminosalicylic acid \[PAS\], ethionamide, ofloxacin, streptomycin \[S\], kanamycin, and enviomycin). On the other hand, the remaining 8 strains (14%) were resistant to at least one agent (3 to H, 1 to S, 3 to E, and 1 to H and S).

The numbers of days from onset to hospitalization, from hospitalization to treatment, and from onset to treatment were 37 days (range, 3--361 days), 2 days (range, 0--9 days), and 41 days (range, 3--364 days), respectively.

3.3. Hospital course and prognostic factors {#sec0010}
-------------------------------------------

Anti-tuberculosis agents were administered to 67 of 68 patients. One patient died on the second day of hospitalization due to ill condition; therefore, no agent was administered. Sixteen patients received additional treatment with HRZE, 6 with HRZS, 7 with HRS, 33 with HRE, 1 with HRZE and LVFX, 1 with HRE and LVFX, one with HRES, one with HR, and one with H and CFLX (She was treated with injections because of poor general condition. CFLX was used instead of LVFX which had not been released as injection preparation in Japan at that time.). INH resistance was detected in 4 cases and treatment was changed to LVFX in 3 cases and TH in 1 case.

The median time lag from hospitalization to anti-tuberculosis agent administration was 2 days (range, 0--9 days), with no difference between survivors and non-survivors.

Fifteen of 68 patients died due to tuberculosis, with a mortality rate of 22.1%. Of the 15 patients, 6 had ARDS. Compared to the mortality rate of 16% among patients without ARDS, the mortality rate was 46.2% among patients who developed ARDS. With regard to patient characteristics, the risk of death within three months increased with increasing age; however, no steady relationship was observed between the risk of death within three months and sex, smoking history, or alcohol intake. The risk of death within three months also increased with worsening PS. Moreover, ARDS, liver dysfunction, and consciousness disturbance were also associated with an increase in the risk of death within three months. Laboratory findings revealed that an increase in BUN levels was associated with an increase in the risk of death within three months ([Table 2](#tbl0002){ref-type="table"}). Furthermore, in order to assess which factors were strongly associated, factors with a *p* value \<0.1 (age, PS, ARDS onset, liver dysfunction, consciousness disturbance, and BUN) were incorporated as the initial explanatory variables. In the subsequent examination by the stepwise method, age, ARDS onset, consciousness disturbance, and BUN were four factors that remained significant ([Table 3](#tbl0003){ref-type="table"}).Table 1Baseline characteristics of patients with miliary tuberculosis (*n *= 68).Table 1ParametersResultsParametersResultsNumber of patients68AFB-positive sputum: positive/total (%)Age, years (range)83 (27--93)Smear49/68 (71%)Sex: male/female18/50PCR50/66 (76%)Smoking history: current/former/never0/10/56MGIT47/55 (85%)Alcohol intake: presence/absence8/59Culture57/68 (84%)  Underlying diseaseCulture of AFB in specimens: positive/total (%)Heart disease15 (22%)Urine8/31 (26%)Diabetes18 (27%)Gastric effusion5/9 (56%)Dementia16 (24%)Scrotal pus12/37 (32%)Malignancy11 (16%)Blood2/20 (10%)Cerebrovascular disease12 (18%)Cerebrospinal fluid0/8 (0%)Renal disease7 (10%)Bronchial lavage fluid4/8 (50%)Liver disease7 (10%)Pleural effusion6/12 (50%)Connective tissue disease with steroid treatment9 (13%)Ascites fluid0/0 (0%)  Aneurysm3 (4%)Histopathological examination positive/total (%)Neuromuscular disease3 (4%)Transbronchial biopsy6/8 (75%)None11 (16%)Bone marrow biopsy9/14 (64%)ARDS onset13 (19%)Body mass index (kg/m^2^)18.8 (12.6--26.5%)SymptomsThe period from onset to hospitalization, days (range)37 (3--361)Fever (≥38 °C)51 (75%)Cough19 (28%)The period from hospitalization to anti-tuberculosis treatment, days (range)2 (0--9)Sputum14 (21%)Dyspnea20 (29%)The period from onset to anti-tuberculosis treatment, days (range)41 (3--364)Loss of appetite44 (65%)General malaise45 (66%)Length of hospital stay, days (range)102 (2--547)Consciousness disturbance8 (12%)Lumbar pain7 (10%)PS (median)3 (1--4%)[^1][^2]Table 2Comparisons of demographic, clinical, and laboratory characteristics between patients with miliary tuberculosis who died within three months (non-survivors) and who survived longer than three months (survivors).Table 2ParametersSurvivors (*n *= 53)Non-survivors (*n *= 15)Crude odds ratio95%CI*p*-valueAdjusted\* odds ratio95%CI*p*-valueLower limitUpper limitLower limitUpper limitAge (years)≤721303.88†1.589.55*p* for trend = 0.0038.14†1.9833.48*p* for trend = 0.00473--7811079--85156≥86149SexFemale37131.00Reference1.00ReferenceMale1620.360.071.760.2060.430.072.600.357Smoking historyAbsence45111.00Reference0.4651.00Reference0.287Presence731.750.397.892.750.4317.72Unknown11----------------Alcohol intakeAbsence46121.00Reference1.00ReferencePresence621.280.237.150.7801.130.158.520.904Unknown11----------------PS1801.00Reference1.00Reference210131533.600.3438.300.2883.750.2949.030.313420119.901.1684.470.0367.640.7182.150.093*p* for trend = 0.017*p* for trend = 0.076SmearNegative1721.00Reference1.00ReferencePositive36133.070.6215.150.1691.810.3010.990.518Drug sensitivity pattern0\*\*3712------0.468 (Fisher\'s exact test)--------1\*\*\*70------------2\*\*\*\*10------------N/A83----------------PaO2/FiO2ratio52.9 -1371.00Reference1.00Reference309 -2650.360.091.350.1280.850.0611.150.900357 -200.400.081.870.2441.610.1025.160.736378 -123*p* for trend = 0.191*p* for trend = 0.610PCRNegative1421.00Reference1.00ReferencePositive39111.970.3910.030.4120.970.146.690.979N/A02----------------MGITNegative80------0.188 (Fisher\'s exact test )--------Positive3611------------N/A94----------------CultureNegative1011.00Reference1.00ReferencePositive43143.260.3827.740.2801.560.1417.710.719ARDS onsetAbsence4691.00Reference1.00ReferencePresence764.381.1916.130.02615.342.13110.250.007Underlying diseaseAbsence110------0.105 (Fisher\'s exact test )--------Presence4215------------Heart diseaseAbsence4491.00Reference1.00ReferencePresence963.260.9311.460.0662.640.6111.480.195DiabetesAbsence39111.00Reference1.00ReferencePresence1441.010.283.710.9841.830.369.260.464DementiaAbsence41111.00Reference1.00ReferencePresence1241.240.334.620.7460.300.051.780.187MalignancyAbsence44131.00Reference1.00ReferencePresence920.750.143.930.7358.090.47139.670.150Cerebrovascular diseaseAbsence42141.00Reference1.00ReferencePresence1110.270.032.310.2330.200.021.980.171Renal diseaseAbsence50111.00Reference1.00ReferencePresence346.061.1831.030.0314.930.6239.430.132Liver diseaseAbsence49121.00Reference1.00ReferencePresence433.060.6015.550.17712.611.03154.210.047Connective tissue disease with steroid treatmentAbsence45141.00Reference1.00ReferencePresence810.400.053.500.4090.580.056.250.657AneurysmAbsence5015------1.000 (Fisher\'s exact test )--------Presence30------------Neuromuscular diseaseAbsence5015------1.000 (Fisher\'s exact test)--------Presence30------------SymptomsFever (≥38 °C)Absence1341.00Reference1.00ReferencePresence40110.890.243.290.8661.250.256.230.785CoughAbsence36131.00Reference1.00ReferencePresence1720.330.071.610.1690.580.093.660.562SputumAbsence41131.00Reference1.00ReferencePresence1220.530.102.660.4370.880.136.050.895DyspneaAbsence4081.00Reference1.00ReferencePresence1372.690.828.870.1031.470.297.350.637Loss of appetiteAbsence2221.00Reference1.00ReferencePresence31134.610.9422.530.0594.190.7024.960.116General malaiseAbsence2031.00Reference1.00ReferencePresence33122.420.619.650.2092.070.4210.050.369Consciousness disturbanceAbsence48121.00Reference1.00ReferencePresence532.400.5011.480.2739.250.82104.240.072Lumbar painAbsence47141.00Reference1.00ReferencePresence610.560.065.050.6052.320.1535.660.545Lymphocyte count2.2-1391.00Reference1.00Reference416-1320.220.041.230.0850.031.901.230.170634.5-1330.330.071.520.1560.124.251.520.702915.2-1410.100.010.930.0430.022.490.930.220*p* for trend = 0.024*p* for trend = 0.220Platelet count2.9-1381.00Reference1.00Reference15.3-1440.460.111.920.2890.400.072.250.30023.3-1330.190.040.830.0270.390.072.160.02732.1-130*p* for trend = 0.025*p* for trend = 0.262CRP0.21-1431.00Reference1.00Reference2.58-1210.390.044.250.4390.730.0510.590.8205.23-1331.080.186.320.9351.810.2314.380.5758.97-1482.670.5812.190.2063.180.4920.810.227*p* for trend = 0.112*p* for trend = 0.183Alb1.5-17101.00Reference1.00Reference2.55-1730.300.071.290.1050.850.145.310.8663.05-1720.200.041.050.0570.250.041.580.141Missing values20------*p* for trend = 0.035------*p* for trend = 0.149BUN7-1301.00Reference1.00Reference13-9114-1634.130.3943.380.2381.490.1218.550.75821-151116.131.88138.470.0116.610.5973.410.124*p* for trend = 0.004*p* for trend = 0.067Cr0.25-1321.00Reference1.00Reference0.54-1410.460.05.70.5500.150.02.80.2010.63-1063.900.623.60.1380.770.18.10.8290.87-1662.440.414.20.3210.570.15.20.618*p* for trend = 0.128*p* for trend = 0.881GOT13-1721.00Reference1.00Reference29-1841.890.3111.680.4942.080.2815.290.47441-1883.780.7020.380.1224.110.4934.330.192Missing values01------*p* for trend = 0.102------*p* for trend = 0.188GPT3-1431.00Reference1.00Reference17-2020.470.073.170.4350.230.031.960.18030-1992.210.509.690.2933.520.3733.680.274Missing values01------*p* for trend = 0.173------*p* for trend = 0.173LDH125-1741.00Reference1.00Reference205-1810.240.022.330.2170.110.011.310.081261-1892.130.558.210.2740.790.125.110.807Missing values01------*p* for trend = 0.188------*p* for trend = 0.927[^3][^4][^5][^6][^7]Table 3Relationships between clinical factors and the risk of death within three months of miliary tuberculosis diagnosis: multivariate analysis.Table 3ParametersSurvivors (*n *= 53)Non-survivors (*n *= 15)Adjusted odds ratio†95% Confidence interval*P* = valueLower limitUpper limitAge (years)≤7213015.5‡1.79134.57*p* for trend = 0.01373--7811079--85156≥86149ARDS onsetAbsence4691.00ReferencePresence761211410.050Consciousness disturbanceAbsence48121.00ReferencePresence5381.531.265258.400.038BUN7-1305.71‡1.1328.77*p* for trend = 0.03513-9114-16321-1511[^8][^9]

4. Discussion {#sec0011}
=============

Traditionally, miliary tuberculosis has been commonly observed as a type of primary tuberculosis. Previous reports on the prognosis of patients with miliary tuberculosis, including, especially, those with ARDS, have noted a high prevalence in young people in their 20 s, with many reporting the mean age ranging from 40 to 60 years [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021], [@bib0022], [@bib0023]. In Japan, a publication from more than 20 years ago reported a mean (±SD) age of 45.3 (±19.3) years [@bib0007]. However, in recent years, a remarkably high proportion of the population of patients with tuberculosis in Japan is characteristically elderly, while having a lower proportion of HIV co-infection and multidrug-resistant tuberculosis; a similar trend is starting to appear in the age distribution of extrapulmonary tuberculosis patients [@bib0024]. The results of the present study reflected this trend, as those aged 80 years or higher were highest in number (41/68 patients; 60%). In this regard, this study reports valuable findings that shed light on the current status of miliary tuberculosis in Japan.

According to previous studies, ARDS develops in association with miliary tuberculosis at a rate of 16--24% [@bib0002], [@bib0003], [@bib0006]. In the present study as well, ARDS was observed at a similar rate of 19% in patients with miliary tuberculosis.

The rate of disease-specific deaths in patients with miliary tuberculosis with ARDS is reportedly high, at 30--90% [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011]. In the present study, disease-specific mortality in patients with ARDS was 46.2%, which was significantly higher compared to 16% in patients who did not develop ARDS. These findings suggest the need for a comprehensive study, when considering the prognosis of miliary tuberculosis, that includes patients with ARDS.

Reports on the prognosis of miliary tuberculosis consistently suggest ARDS to be associated with poor prognosis [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011]. Other reported prognostic factors include old age [@bib0016], immunodeficiency [@bib0016], [@bib0019], diabetes [@bib0022], delayed discovery [@bib0015], [@bib0017], psychiatric disorders [@bib0008], [@bib0020], elevated liver enzymes [@bib0015], renal dysfunction [@bib0015], [@bib0019], malnutrition [@bib0015], [@bib0021], thrombocytopenia [@bib0020], [@bib0022], and greater extent of ground glass opacity [@bib0023], although no consistent outcomes have been obtained with regard to this aspect. Many previous reports are from high-prevalence countries, with high proportions of subjects being relatively young patients; few reports mention old age as a prognostic predictor [@bib0016]. Meanwhile, one of the characteristics of the tuberculosis population in Japan is that the number of elderly patients is remarkably high, and many reports suggest old age as a prognostic predictor [@bib0025], [@bib0026], [@bib0027]. In our patients, in addition to the presence/absence of ARDS, age was considered to be strongly associated with the risk of death within three months. Therefore, we conducted analyses by constantly adjusting for age and presence/absence of ARDS to obtain odds ratios for each factor. As a result, ARDS onset, old age, PS, liver dysfunction, consciousness disturbance, and high BUN levels were identified as risk factors for death within three months. We further examined these factors using the stepwise method to assess those showing strong associations, and found ARDS onset, old age, consciousness disturbance, and high BUN levels to be significant factors. With regard to the causes and extent of consciousness disturbance, many aspects remain unclear, as the present study was retrospective in nature. While our subjects likely included those with meningitis and brain tuberculosis, head CT or MRI examinations were not performed, as the condition of patients presenting with consciousness disturbance was poor, with the GCS of 12 or less.

As for high BUN levels, given that no steady relationships were observed between the risk of death within three months and presence/absence of renal disease or serum creatinine levels, our observation might have reflected dehydration tendencies or hypercatabolism.

In Japan, nutritional status is often reported as a prognostic factor for tuberculosis. However, the present study did not find nutritional status to be an independent prognostic predictor. This could be explained by the fact that the nutritional condition of patients with miliary tuberculosis had already deteriorated somewhat at the time of hospital admission, and was thus unlikely to serve as a predictor of prognosis.

Prognostic factor might be not specific to miliary TB: old age, ARDS, consciousness disturbance and high BUN levels would be expected to be predictors of mortality in any condition.

There are some limitations to this study. First, this study was conducted at a single center with a small sample size. In particular, the number of patients with ARDS was quite low. Data on co-morbidities from clinical records were incomplete, but there was no reason to assume a systematic bias for missing information, since they were obtained from the records. Moreover, as the present study used a retrospective design, the degree of consciousness disturbance and the extent of dementia were unclear, and the causes of underlying diseases including renal disease and liver disease were unknown.

In summary, the present study examined prognostic factors in patients with miliary tuberculosis including those with ARDS in Japan, and revealed that ARDS onset, old age, presence/absence of consciousness disturbance, and high BUN levels are independent poor prognostic factors.

5. Conclusion {#sec0012}
=============

In patients with miliary tuberculosis, the complication of ARDS was observed in 19%. Old age, ARDS, consciousness disturbance, and high BUN levels were factors associated with poor prognosis.
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[^1]: Data are presented as median (range) or number (%).

[^2]: ARDS: acute respiratory distress syndrome; PS:performance status; AFB: acid-fast bacteria; BMI: body mass index.

[^3]: \*: Adjusted for age and presence/absence of ARDS. Odds ratios for age and presence/absence of ARDS were only adjusted for other factors mutually. †: Odds ratio for each increase in age group was obtained, when patients were divided into three groups by age.

[^4]: \*\*: Sensitive to all anti-tuberculosis agents.

[^5]: \*\*\*: Resistance to at least one anti-tuberculosis agent.

[^6]: \*\*\*\*: Resistance to two anti-tuberculosis agents.

[^7]: ARDS: acute respiratory distress syndrome, PS: Performance Status, AFB: Acid-fast bacteria, BMI: body mass index, WBC: white blood cell, Alb: Albumin, CRP: C**-**reactive protein, Cr: creatinine, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase.

[^8]: †: Four variables in the table were selected with age, presence/absence of ARDS during the disease course, PS, presence/absence of consciousness disturbance, and presence/absence of liver disease as explanatory variables with a removal probability of 0.1 by backward elimination.

[^9]: ‡: For age and BUN levels, odds ratios for each increase in group were obtained. ARDS: acute respiratory distress syndrome.
